HOME > Conference > Detailed Program
GBC1
Keynote Speech & Plenary Session
Basic Information
Date June 26(Wed), 14:00 - 18:00 Location GrandBallroom (5F) Floor Info
Overview TBD
Schedule
Time Program Speaker Data
14:00-14:10 (10') - - -
Opening Ceremony
14:10-14:15 (5') - - -
14:15-14:18 (3') - - -
14:18-14:21 (3') - - -
14:21-14:24 (3') - - -
14:24-14:30 (6') - - -
Keynote Speech
14:30-15:00 (30') - - -
15:00-15:30 (30') - - -
15:30-16:00 (30') - - -
16:00-16:20 (20') -
Plenary Session
16:20-16:40 (20') - - -
16:40-17:00 (20') - - -
17:00-17:20 (20') - - -
17:20-18:00 (40') - - -
Location Information
[GBC 2] Recombinant Protein Products Forum

Current Trends and Future of Biosimilars

BAT1406 is an adalimumab biosimilar that has been systematically compared to the original drug during the R&D processes, including a pharmacodynamic evaluation in acute and chronic inflammation animal models. Through specific binding to TNF-α and the neutralization effect, BAT1406 blocks interaction of TNF-α with cell surface TNF receptors p55 and p75 and thus inhibits its inflammatory effect.

Adalimumab was the world's first approved fully human anti-TNF-α monoclonal antibody and has been approved for eight different indications including rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.  
질의 접수
발표Data.pdf

난이도 : 중